2015
CBM-05FUNCTIONAL DIFFERENCES BETWEEN PD-1+ AND PD-1– CD4+ T EFFECTOR CELLS IN HEALTHY DONORS AND PATIENTS WITH GLIOBLASTOMA
Goods B, Lowther D, Lucca L, Hernandez A, Lerner B, Gunel M, Raddassi K, Simon J, Coric V, Love J, Hafler D. CBM-05FUNCTIONAL DIFFERENCES BETWEEN PD-1+ AND PD-1– CD4+ T EFFECTOR CELLS IN HEALTHY DONORS AND PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2015, 17: v70-v70. PMCID: PMC4638709, DOI: 10.1093/neuonc/nov211.05.Peer-Reviewed Original ResearchThe TIGIT/CD226/CD155 axis is differentially expressed in MS and glioblastoma: implications for autoimmunity and tumor immune escape. (P4.043)
Lowther D, Ramanan S, DeBartolo D, Park C, Duan X, Hafler D, Pitt D. The TIGIT/CD226/CD155 axis is differentially expressed in MS and glioblastoma: implications for autoimmunity and tumor immune escape. (P4.043). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p4.043.Peer-Reviewed Original ResearchImmune Infiltrates Expressing Podoplanin (PDPN) are Present in Multiple Sclerosis but not Glioblastoma (S12.002)
Nylander A, Ramanan S, Debartolo D, Park C, Hafler D, Pitt D. Immune Infiltrates Expressing Podoplanin (PDPN) are Present in Multiple Sclerosis but not Glioblastoma (S12.002). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.s12.002.Peer-Reviewed Original Research
2014
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
Sampson J, Vlahovic G, Desjardins A, Friedman H, Baehring J, Hafler D, Rollin L, Coric V, Perez S, Reardon D. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal Of Clinical Oncology 2014, 32: tps2101-tps2101. DOI: 10.1200/jco.2014.32.15_suppl.tps2101.Peer-Reviewed Original Research